Lactobacillus salivarius is a bacterium used in probiotic supplements for oral, digestive and other health goals. Selected preparations have the strongest evidence for preventing breast inflammation during breastfeeding and reducing eczema severity. Benefits depend on the strain and condition; oral results are inconsistent. Short-term tolerance is generally favorable, but allergies and infection risk matter. Routine supplementation has not been shown to slow human aging or extend life. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Oral inflammation and pocket depth | No probiotic-specific optimal range; change from baseline | Measure oral outcome |
| Eczema severity score | No probiotic-specific target; change from baseline | Measure skin outcome |
| Serum urate, only for established gout | No probiotic-specific functional range; baseline change against clinician’s disease target | Follow gout biology |
| Blood count, chemistry, or inflammatory tests | No established routine target; clinically indicated abnormalities | Investigate illness |
| Stool or oral species abundance | No established healthy or optimal L. salivarius range; clinical change is the endpoint | Limited research utility; routine serial testing has no demonstrated value |
Cadence: Baseline; tolerance at 1–2 weeks; oral/intestinal outcomes at 4–8 weeks; eczema at 8–16 weeks; other indications at their study interval. No validated laboratory panel or commercial microbiome range.